40296-46-6

Basic information

• Product Name: Ethyl 4,6-dichloronicotinate
• Synonyms: 4,6-DICHLOROPYRIDINE-3-CARBOXYLIC ACID ETHYL ESTER;4,6-DICHLORONICOTINIC ACID ETHYL ESTER;ETHYL 4,6-DICHLORONICOTINATE;2,4-Dichloro-5-carbethoxypyridine;4,6-Dichloronicotinic acid ethyl ester ,97%;ethyl 4,6-dichloronicotinate (en);Ethyl 4,6-dichloronicotinate ,97%;ethyl 4,6-dichloropyridine-3-carboxylate
• CAS NO: 40296-46-6
• Molecular Formula: C₈H₇Cl₂NO₂
• Molecular Weight: 220.05
• Product Categories: Pyridine series;Boronic Acid
• Mol File: 40296-46-6.mol

Chemical Properties

• Melting Point: 32-34°
• Boiling Point: 85°C/0.01mmHg(lit.)
• Flash Point: 120.9 °C
• Appearance: Yellow/Liquid
• Density: 1.367 g/cm³
• Vapor Pressure: 0.00484mmHg at 25°C
• Refractive Index: 1.54
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Soluble in methanol.
• PKA: -1.24±0.10(Predicted)
• CAS DataBase Reference: Ethyl 4,6-dichloronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4,6-dichloronicotinate(40296-46-6)
• EPA Substance Registry System: Ethyl 4,6-dichloronicotinate(40296-46-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 40296-46-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4,6-dichloronicotinate is used as a key intermediate for the preparation of (acylamino)aminonaphthyridinones, which are analogs of novobiocin and act as Hsp90 inhibitors. These compounds exhibit antitumor activities in human breast cancer cell lines and can influence apoptosis and cell cycle progression, making them promising candidates for cancer treatment.
Used in Organic Synthesis:
Ethyl 4,6-dichloronicotinate is utilized as an important raw material and intermediate in organic synthesis, where it can be employed to create a wide range of chemical products. Its reactivity and structural features make it a valuable component in the development of new molecules with various applications.
Used in Agrochemical Industry:
In the agrochemical industry, Ethyl 4,6-dichloronicotinate is used as a starting material for the synthesis of various agrochemicals, such as pesticides and herbicides. Its role in this industry is to provide a foundation for the development of effective and environmentally friendly solutions for crop protection.
Used in Dye Industry:
Ethyl 4,6-dichloronicotinate is also used as a fine chemical intermediate in the dye industry. Its chemical properties allow it to be incorporated into the synthesis of various dyes, contributing to the development of new colorants with improved properties and applications.

InChI:InChI=1/C8H7Cl2NO2/c1-2-13-8(12)5-4-11-7(10)3-6(5)9/h3-4H,2H2,1H3

Upstream product

• 6975-44-6 4,6-dihydroxynicotinic acid ethyl ester 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 73027-79-9 4,6-dichloro-nicotinic acid 
• 64-17-5 ethanol 
• 141-52-6 sodium ethanolate 
• 107836-75-9 4,6-dichloropyridine-3-carbonyl chloride 
• 6975-44-6 4-Hydroxy-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid ethyl ester 

Downstream Products

• 73027-79-9 4,6-dichloro-nicotinic acid 
• 845655-96-1 6-chloro-4-hydrazino-nicotinic acid ethyl ester 
• 959162-97-1 6-chloro-4-ethylamino-nicotinic acid ethyl ester 
• 73998-95-5 2,4-dichloro-5-hydroxymethylpyridine 
• 1005756-71-7 ethyl 6-chloro-4-(3-fluorophenethylamino)nicotinate 
• 449811-28-3 ethyl 6-chloro-4-(methylamino)pyridine-3-carboxylate 
• 1011464-52-0 6-chloro-4-isopropylamino-nicotinic acid ethyl ester 
• 821791-58-6 ethyl 4-chloro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 55934-01-5 2,3,5-trichloropyridine 
• 166526-03-0 4,6-dichloropyridine-3-carbonitrile 
• 821791-31-5 ethyl 6-chloro-4-(2,4-difluoroanilino)nicotinate 
• 372117-94-7 3-ethoxycarbonyl-4-(3-chloro-4-methoxybenzylamino)-6-chloropyridine 
• 888482-53-9 4-(4-bromo-2-methyl-phenylamino)-6-chloro-nicotinic acid ethyl ester 
• 888482-62-0 4-(4-iodo-2-methyl-phenylamino)-6-chloro-nicotinic acid ethyl ester 

Relevant articles and documents

Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization

Through a structure-based molecular hybridization approach, a novel series of diarylnicotinamide derivatives (DANAs) targeting the entrance channel of HIV-1 NNRTIs binding pocket (NNIBP) were rationally designed, synthesized and evaluated for their anti-H

Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90

Hsp90 is an ATP-dependent chaperone known to be overexpressed in many cancers. This way, Hsp90 is an important target for drug discovery. Novobiocin, an aminocoumarin antibiotic, was reported to inhibit Hsp90 targeting C-terminal domain, and showed anti-proliferative properties, leading to the development of new and more active compounds. Consequently, a new set of novobiocin analogs derived from 1,6-naphthyridin-2(1H)-one scaffold was designed, synthesized and evaluated against two breast cancer cell lines. Subsequently, cell cycle progression and apoptosis were conducted on best candidates, finally Western Blot analysis was performed to measure their ability to induce degradation of Hsp90 client proteins.

Novel approach towards 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones exploiting cross-coupling and SNAr reactions of a dihalogenated compound

A new route towards the synthesis of a series of 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones in moderate to good yields is reported. The strategy involves the preparation of a 3,7-dihalogenated compound that undergoes differential functionalization using palladium-catalyzed cross-coupling and SNAr reactions.

Bicyclic heterocyclic anthranilic diamides as ryanodine receptor modulators with insecticidal activity

The diamide insecticides act on the ryanodine receptor (RyR). The synthesis of various bicyclic anthranilic derivatives is reported. Their activity against the insect ryanodine receptor (RyR) and their insecticidal activity in the greenhouse is presented,

Quinolone amides as antitrypanosomal lead compounds with In Vivo activity

Human African trypanosomiasis (HAT) is a major tropical disease for which few drugs for treatment are available, driving the need for novel active compounds. Recently, morpholino-substituted benzyl amides of the fluoroquinolone-type antibiotics were identified to be compounds highly active against Trypanosoma brucei brucei. Since the lead compound GHQ168 was challenged by poor water solubility in previous trials, the aim of this study was to introduce structural variations to GHQ168 as well as to formulate GHQ168 with the ultimate goal to increase its aqueous solubility while maintaining its in vitro antitrypanosomal activity. The pharmacokinetic parameters of spray-dried GHQ168 and the newly synthesized compounds GHQ242 and GHQ243 in mice were characterized by elimination half-lives ranging from 1.5 to 3.5 h after intraperitoneal administration (4 mice/compound), moderate to strong human serum albumin binding for GHQ168 (80%) and GHQ243 (45%), and very high human serum albumin binding (>99%) for GHQ242. For the lead compound, GHQ168, the apparent clearance was 112 ml/h and the apparent volume of distribution was 14 liters/kg of body weight (BW). Mice infected with T. b. rhodesiense (STIB900) were treated in a stringent study scheme (2 daily applications between days 3 and 6 postinfection). Exposure to spray-dried GHQ168 in contrast to the control treatment resulted in mean survival durations of 17 versus 9 days, respectively, a difference that was statistically significant. Results that were statistically insignificantly different were obtained between the control and the GHQ242 and GHQ243 treatments. Therefore, GHQ168 was further profiled in an early-treatment scheme (2 daily applications at days 1 to 4 postinfection), and the results were compared with those obtained with a control treatment. The result was statistically significant mean survival times exceeding 32 days (end of the observation period) versus 7 days for the GHQ168 and control treatments, respectively. Spray-dried GHQ168 demonstrated exciting antitrypanosomal efficacy.

ROR NUCLEAR RECEPTOR MODULATORS

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

Differential functionalization of 1,6-naphthyridin-2(1H)-ones through sequential one-pot Suzuki-Miyaura cross-couplings

A practical synthesis of 7-chloro-3-iodo-1-methyl-1,6-naphthyridin-2(1H)- one is described that starts from 2-chloro-4-(methylamino)nicotinaldehyde. The dihalo compound then undergoes sequential, site-selective Suzuki-Miyaura cross-coupling reactions to afford highly functionalized 1,6-naphthyridones in good yields. One-pot, sequential, site-selective Suzuki-Miyaura cross-coupling reactions of 7-chloro-3-iodo-1-methyl-1,6-naphthyridin-2(1H)-one afforded highly functionalized 1,6-naphthyridones in good yields. Copyright

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

Pyridine-3-carboxamide-6-yl-ureas as novel inhibitors of bacterial DNA gyrase: Structure based design, synthesis, SAR and antimicrobial activity

The development of antibacterial drugs based on novel chemotypes is essential to the future management of serious drug resistant infections. We herein report the design, synthesis and SAR of a novel series of N-ethylurea inhibitors based on a pyridine-3-carboxamide scaffold targeting the ATPase sub-unit of DNA gyrase. Consideration of structural aspects of the GyrB ATPase site has aided the development of this series resulting in derivatives that demonstrate excellent enzyme inhibitory activity coupled to potent Gram positive antibacterial efficacy.